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A B S T R A C T

Background: The heterogeneity in symptomatology and phenotypic proﬁle attributable to COVID-19 is widely
unknown. The objective of this manuscript is to conduct a trans-ancestry genome wide association study
(GWAS) meta-analysis of COVID-19 severity to improve the understanding of potentially causal targets for
SARS-CoV-2.
Methods: This cross-sectional study recruited 646 participants in the UAE that were divided into two phenotypic groups based on the severity of COVID-19 phenotypes, hospitalized (n=482) and non-hospitalized
(n=164) participants. Hospitalized participants were COVID-19 patients that developed acute respiratory distress syndrome (ARDS), pneumonia or progression to respiratory failure that required supplemental oxygen
therapy or mechanical ventilation support or had severe complications such as septic shock or multi-organ
failure. We conducted a trans-ancestry meta-analysis GWAS of European (n=302), American (n=102), South
Asian (n=99), and East Asian (n=107) ancestry populations. We also carried out comprehensive post-GWAS
analysis, including enrichment of SNP associations in tissues and cell-types, expression quantitative trait loci
and differential expression analysis.
Findings: Eight genes demonstrated a strong association signal: VWA8 gene in locus 13p14¢11 (SNP
rs10507497; p=9¢54 x10-7), PDE8B gene in locus 5q13¢3 (SNP rs7715119; p=2¢19 x10-6), CTSC gene in locus
11q14¢2 (rs72953026; p=2¢38 x10-6), THSD7B gene in locus 2q22¢1 (rs7605851; p=3¢07x10-6), STK39 gene in
locus 2q24¢3 (rs7595310; p=4¢55 x10-6), FBXO34 gene in locus 14q22¢3 (rs10140801; p=8¢26 x10-6), RPL6P27
gene in locus 18p11¢31 (rs11659676; p=8¢88 x10-6), and METTL21C gene in locus 13q33¢1 (rs599976; p=8¢95
x10-6). The genes are expressed in the lung, associated to tumour progression, emphysema, airway obstruction, and surface tension within the lung, as well as an association to T-cell-mediated inﬂammation and the
production of inﬂammatory cytokines.
Interpretation: We have discovered eight highly plausible genetic association with hospitalized cases in
COVID-19. Further studies must be conducted on worldwide population genetics to facilitate the development of population speciﬁc therapeutics to mitigate this worldwide challenge.
Funding: This review was commissioned as part of a project to study the host cell receptors of coronaviruses
funded by Khalifa University’s CPRA grant (Reference number 2020-004).
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Research in context
Evidence before this study
The heterogeneity in symptomatology and phenotypic proﬁle
attributable to COVID-19 disease may vary across different populations, suggesting a complex interaction between the host
genetics and virus that inﬂuence the disease outcome. Multiple
genome-wide association studies (GWAS) have demonstrated
an association between host genetic architecture and vulnerability to COVID-19 outcome. Two loci that achieved genomewide signiﬁcance are identiﬁed in a gene cluster on chromosome 3p21¢31 as a genetic susceptibility region, and in chromosome 9 conﬁrming the potential involvement of the ABO bloodgroup system as a factor that contributes to severity of infection. GWAS studies in the United Kingdom have pointed to
associations with loci on chromosome 19p13¢2 and 21q22¢1
and identiﬁed risk factors on chromosomes 2, 6, 7, 8, 10, 16,
and 17.
Added value of this study
Our study presents a trans-ancestry GWAS meta-analysis of
European (n=302), American (n=102), South Asian (n=99), and
East Asian (n=107) ancestry populations to explore new genotypes associated to COVID-19 symptom severity, in a variety of
ethnic populations that will yield to novel genetic association.
We describe strong association signals from genes on chromosomes 2q22¢1, 2q24¢3, 5q13¢3, 11q14¢2, 13p14¢11, 13q33¢1,
14q22¢3, and 18p11¢31, which carry genes that are expressed
in the lung, associated to tumour progression, emphysema, airway obstruction, and surface tension within the lung, as well as
an association to T-cell-mediated inﬂammation and the production of inﬂammatory cytokines. Cell-type enrichment analysis demonstrated that there was an enrichment for lung tissue
expression and donors. Identifying genetic variants associated
to COVID-19 susceptibility and severity may uncover novel biological insights into disease pathogenesis and identify mechanistic targets for therapeutic and vaccine development.
Implications of all the available evidence
Performing GWAS across different racial and ethnic populations
to identify genes and haplotypes associated with differential
factors of infection and clinical outcome, as well as vaccine
responses, is crucial. Some of these associations may lead to
therapeutic approaches due to the expression in the lungs.
Improving fundamental knowledge and underlying biological
pathway of COVID-19 heterogenous phenotypes is critical to
mitigating this disease.

remains poorly understood [8 10]. Severity of COVID-19 phenotypes
vary across different populations, suggesting a complex interaction
between the host genetics, and virus that inﬂuence the disease outcome [11]. Identifying genetic variants associated to COVID-19 susceptibility and severity may uncover novel biological insights into
disease pathogenesis and identify mechanistic targets for therapeutic
and vaccine development.
Although risk factors, disease management and health systems
contribute to the heterogenous COVID-19 symptom phenotypes,
multiple genome-wide association studies (GWAS) have demonstrated an association between host genetic architecture and vulnerability to COVID-19 outcome. Two loci that achieved genome-wide
signiﬁcance are located in chromosome 9 near the ABO gene, and a
signal in chromosome 3 near a cluster of genes (SLC6A20, CXCR6,
CCR1, CCR2, and CCR9) that play a role in immune function [12].
Recent papers have validated the two previous loci, and found novel
risk variants at chromosome 1q22, 6p21¢33, 12q24¢13, 19p13¢3, and
21q22¢1 associated with severe COVID-19 [13 16]. Further investigation in independent datasets of various genetic populations is needed
to investigate genetic variation among individuals infected with
SARS-CoV-2. Genetic variability due to population-speciﬁc genetic
characteristics, including variants, admixture and ancestral haplogroup distribution may lead to differential magnitudes of the variants’ effect. Genetic heterogeneity contributes to clinical health
disparities, where there is a lack of genetic studies conducted on the
Middle Eastern population. Admixture and consanguinity have
jointly affected the genetic diversity in the Middle East population
[17,18]. Hence, our study provides the unique advantage of obtaining
samples from the Middle Eastern population, an underrepresented
region in genetic studies, and explore new genotypes in this population that will yield to novel genetic association.
We performed the ﬁrst GWAS in the United Arab Emirates (UAE)
to identify genetic variants that are associated with hospitalized cases
of COVID-19 patients. The objective of this study is to conduct a
trans-ancestry GWAS meta-analysis in a variety of ethnic populations
to investigate host genetic factors associated to COVID-19 severity
and further understand the biological pathways that are triggering
these heterogenous phenotypes. We also utilized approaches and
strategies to translate genetic risk loci of potential candidate genes
and tissue-speciﬁc expression quantitative trait loci (eQTL) data to
predict the causal genes. We performed gene-set enrichment analysis
with GWAS summary statistics to identify the potential biological
pathways for COVID-19 hospitalizations. This landscape of potential
pleiotropic genes and biological pathways will help us to understand
risk of severe COVID-19 disease and assist early detection and
improve pharmaceutical therapy.
2. Methods
2.1. Ethics Statement

1. Introduction
Coronavirus disease 2019 (COVID-19), the disease caused by the
viral infection of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has rapidly evolved into a global pandemic [4]. The
heterogeneity in symptomatology, phenotypic proﬁle, and comorbidities attributable to COVID-19 disease is widely unknown. Most of
the infected persons (»80%) present with asymptomatic or mild
symptoms, yet »15% of cases are hospitalized with moderate and
severe symptoms, and »5% are fatal [5,6]. Severe COVID-19 disease
has been responsible for ~5.00 million deaths worldwide, mainly due
to bilateral interstitial pneumonia and acute respiratory distress syndrome [7]. While moderate and severe symptoms of persons infected
with COVID-19 are associated with older age, male gender and preexisting comorbid conditions, the pathogenesis of the disease

An informed written consent form was obtained from all participants, in accordance with the Declaration of Helsinki. Informed consent was obtained from a family member of patients who were on
ventilators with a signed agreement by a supervising physician. All
data was de-identiﬁed prior to use. This study has been approved by
the local ethics committee at Abu Dhabi Health COVID-19 Research
Ethics Committee (DOH/DQD/2020/538), Dubai Scientiﬁc Research
Ethics Committee (DSREC-04/2020_09) and SEHA Research Ethics
Committee (SEHA-IRB-005).
2.2. Study Participants and Recruitment
This cross-sectional study recruited 646 consenting participants
that have tested positive for SARS-CoV-2 by Real-Time Polymerase
Chain Reaction (RT-PCR) via nasopharyngeal swabs. Participants
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were prospectively recruited from six collection sites across the UAE
including medical centres, hospitals, and quarantine camps, from
April 1, 2020, to January 31, 2021, as demonstrated in Supplementary
Figure 1. The selection criteria were: [1] positive COVID-19 test for a
single individual, [2] resident of the UAE, and [3] able to provide an
informed consent and complete the survey. Information about the
study was provided to potential participants. Consenting participants
were provided with a questionnaire that includes details on the
demographic characterization, risk factors, and symptomatology,
which were cross-checked with the electronic health record. Reporting of the study design was done in adherence to the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines [19].
After the participants were tested for the COVID-19 infection,
twice in a 3-day waiting period, blood samples were collected in a
sterile 5ml sample tube supplemented with ethylenediaminetetraacetic acid from the cubital vein. Samples were transported in a
sealed biohazard bag using a cool transport container to Khalifa University Centre for Biotechnology in Abu Dhabi for genotyping and
analysis.
2.3. Binary Phenotype Deﬁnition
The severity of COVID-19 classiﬁcation can be grouped into ﬁve
stages of illness categories: asymptomatic, mild, moderate, severe
and critical [20]. Patients are classiﬁed as asymptomatic if they have
no symptoms that are consistent with COVID-19. Patients with mild
illness are individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache,
muscle pain, nausea, vomiting, diarrhoea, loss of taste and smell) but
do not have shortness of breath, dyspnoea, or abnormal chest imaging. Moderate COVID-19 patients were those with lower respiratory
disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) 94% on room air at sea level and require hospitalization. Severe illness is deﬁned as patients who have
SpO2 <94% on room air at sea level, a ratio of arterial partial pressure
of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg,
respiratory frequency >30 breaths/min, or lung inﬁltrates >50%, and
require hospitalization. Critical illness are patients who have respiratory failure, septic shock and/or multiple organ dysfunction, and
require hospitalization.
The classiﬁcations of COVID-19 severity were taken as the worst
classiﬁcation during the patient’s hospital stay. These assessments
were done by at least two physicians and were further veriﬁed by the
information derived from the participant questionnaire. In this study,
to identify the susceptibility genetic loci contributing to hospitalized
cases for COVID-19, the moderate, severe, and critical COVID-19
patients were deﬁned as “cases”, and the asymptomatic and mild
COVID-19 patients were deﬁned as “controls”. Cases for the COVID19 phenotype group were deﬁned as hospitalized (n=482), where
patients were hospitalized with COVID-19 as primary reason for
admission, due to [1] lower respiratory disease, which was deﬁned
by the use of respiratory support or individuals with assisted respiratory distress syndrome (ARDS), pneumonia or progression to respiratory failure that requires supplemental oxygen therapy or
mechanical ventilation support, [2] severe complications such as septic shock or multi-organ failure, or [3] mortality. These phenotypes
were readily extracted from the electronic health records, recorded
by two physicians, as well as information derived from the surveys.
Controls for the COVID-19 group were deﬁned as non-hospitalized
(n=164) participants that did not require hospitalization, due to
asymptomatic or mild symptoms. As per the UAE law, patients who
are asymptomatic or have mild symptoms are advised to isolate at
home, as opposed to visiting the hospital or a quarantine camp.
Therefore, given that most of the patients were collected from a hospital site, the number of COVID-19 patients who showed
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asymptomatic or mild symptoms that did not require hospitalization
were much lower than the number of patients who had moderate/
severe/critical COVID-19 symptoms. Therefore, this study was not
able to capture a higher number of control participants.
2.4. DNA extraction, genotyping and imputation
DNA was extracted using the automated MagPurix 12 system
according to the manufacturer’s protocol. DNA was quantiﬁed using
the DS-11 Series of Spectrophotometer/Fluorometer (DeNovix). Genotyping was performed using the Inﬁnium Global Screening Array-24
v3.0 BeadChip (Illumina, Inc., San Diego, CA, USA) according to the
manufacturer’s protocol, which contained 654,027 genetic markers
and developed by Avera Institute for Human Genetics (South Dakota,
USA). The Inﬁnium Global Screening Array-24 v3.0 BeadChip would
be best suited for this ethnically diverse cohort because it features a
broad spectrum of diverse exonic content, including both cross population and population speciﬁc markers (EUR: 52,980 markers; EAS:
31,375 markers; AMR: 45,977 markers; AFR: 43,122 markers; SAS:
40,298 markers).
We then performed stringent quality controls (QC) for both samples and Single nucleotide polymorphisms (SNPs) to ensure subsequent robust association tests. Samples that failed to reach a 98.0%
call rate were reanalysed. Samples were excluded for the following
reasons: 1) duplicated samples, 2) discrepancies between reported
sex and genetically inferred sex, 3) per-sample call rate <98%, 4) heterozygosity outlier (§3), 5) unusually high number of singleton genotypes, and 6) related individuals to second degree (pairwise identityby-state (PI_HAT)>0.5, family sets with the lowest call rate were
removed). SNPs were excluded due to: 1) low minor allele frequency
(<0¢01), 2) low genotyping rate (<95%), and 3) deviation from
Hardy-Weinberg equilibrium (p<10-6) signiﬁcance level. After quality control, 438,617 variants passed ﬁlters. Subsequently, principal
component analysis (PCA) was performed to stratify by calculating
the ﬁrst ten principal component (PCs) per individual, after merging
with samples from the Phase 3 multi-ethnic 1000 Genomes Projects
panel. Details on the number of samples and SNPs that did not pass
quality control are outlined in Supplementary Figure 1.
Genotypes were prephased and imputed with untyped markers
(»39M) using the Phase 3 multi-ethnic 1000 Genomes Projects panel,
as the reference based on the human genome assembly hg19 (https://
mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html), and was carried out by using BEAGLE, using standard protocols and recommended settings. Imputation was performed on both autosomal and
sex chromosomes. A study conducted in the Kuwaiti-Arab population
demonstrated that the 1000G phase 3 imputation panel is able to
capture the appropriate genotype frequencies of the imputed
markers with those genotypes in the population from the region,
when comparing to the Kuwait Arab Exome Variant Database [21]
and the Greater Middle East Variome project [22]. Post imputation
quality control measures (genotyping rate < 95%, call rate < 98%,
MAF > 1%, HWE p > 1.0 £ 10 6) were conducted, and a total of
9,175,654 variants passed ﬁlters.
2.5. Statistical analysis
The statistical analysis was conducted as a case-control panel,
with controls characterized as non-hospitalized symptoms and cases
characterized as hospitalized symptoms, with the use of PLINK (version 1¢9), R (version 3¢4) and SPSS (version 16¢0). Haploview v4¢1
[23] was used to perform visualization maps, and regional plots were
created using LDlink, with varying window size for optimal visualization [24].
To explore non-genetic associations with COVID-19 hospitalization, the following factors were investigated: [1] demographic variables (age, gender, nationality,); [2] risk factors (body mass index
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(BMI), blood type, current smoking, alcohol intake); [3] symptoms
(fever, cough, headache, fatigue, diarrhoea, loss of taste or smell,
arthralgia, conjunctivitis, chills, malaise, nausea, sore throat, vomiting, sneezing and dyspnoea); and [4], pre-existing conditions (cardiovascular condition, chronic lung disease, diabetes mellitus,
immunosuppressive condition, neurological disorder, metabolic disease, and renal disease). These variables will be investigated in association to hospitalization for COVID-19 using Pearson x2 for
descriptive statistical test and multivariate logistic regression models.
Multivariate regression models adjusted for age (continuous), sex,
ancestry, current BMI (underweight, normal weight, overweight,
obese), and presence of pre-existing conditions.
For case-control comparisons, we tested for association using
logistic regression, assuming additive allelic effects for genotyped
and imputed SNPs. Genotypes were exported, in Genome Reference
Consortium human build 37 (GRCHb37) and Illumina ‘source’ strand
orientation, using the Genotype Studio PLINK input report plugin
v¢2-1-4. To assess the association of a given SNP with COVID-19
severity, the allelic frequencies were compared by means of a x2 statistic, which yielded an individual p-value for each combination of
SNP and allelic model. A quantile-quantile (Q-Q) plot analysis was
carried out to check whether the distribution of the inﬂation p-values
deviated from the expected distribution under the null hypothesis of
no genetic association and investigate if the overall signiﬁcance of
the genome-wide associations is due to potential impact of population stratiﬁcation. Systematic bias and the impact of population stratiﬁcation was evaluated by calculating the genomic control inﬂation
factor [λ GC] and noted for each analysis. A Manhattan plot was generated with -log10 p-values.
To reduce technical confounders and population stratiﬁcation, the
participants were analysed separately by ethnic group depending on
the genetic threshold. We performed GWAS by ancestry group followed by trans-ancestry meta-analysis across all ancestry groups.
The 1000 genome v3 reference panel was used for genomic population assessment and divided into the following ﬁve super populations: African (AFR), admixed from the Americas (AMR), East Asian
(EAS), South Asian (SAS), and European (EUR). Genetic ancestry was
estimated using PCs performed based on uncorrelated SNPs. Using all
10 ancestry PCs, the median and variance for each population was
calculated, followed by the Mahalanobis distance for each population
sample. The sample in this study was then assigned to the 1000
genome v3 reference panel population with the minimum Mahalanobis distance. In each individual ethnic group, we performed association testing under an additive model for the effect of the risk allele
while adjusting for age, sex, and population stratiﬁcation. To adjust
for population structure, we ﬁrst used principal component analysis
(PCA) after LD pruning from the initial pool. As a measure to control
for population stratiﬁcation, two eigenvectors were used in subsequent adjustment analyses. Association summary statistics from
GWAS within each ancestry group were then combined by ﬁxedeffects meta-analysis with inverse variance weights was used to
obtain the combined effects for each SNP. We also computed the test
statistics for heterogeneity of effect among studies for each variant
using Cochran’s Q-test. We removed variants with heterogeneity pvalue<0.001 from the meta-analyses. Genome-wide association
markers surpassed a conservative Bonferroni-corrected signiﬁcance
threshold of discovery p<5£10 8, whereas markers that identiﬁed
associations that reached a suggestive association threshold
of p<5£10 5.

Protein Atlas (http://www.proteinatlas.org) [25 28] and the Genotype-Tissue Expression v7 (GTEx) tool were utilized [29 31]. Both
Human Protein Atlas and GTEx have provided an atlas of the regulatory landscape of gene expression and splicing variation in a broad
selection of primary human tissues. Nearly all protein-coding genes
have one local variant associated with expression changes and the
majority have common variants affecting alternative splicing
(FDR<5%). To gain insight into the cell types that are important for
COVID-19, we evaluated whether expression weights for lung tissues
were investigated in association to gene enrichment variants. We
interrogated coding variants for each lead SNP and its proxies
(R2>0.8) using Ensembl and HaploReg.
The GTEx was established to characterize human transcriptomes
and has created a reference resource of gene expression levels from
non-diseased tissues, including genotype, gene expression, and histological data. GTEx database captures the estimated effect size of an
eQTL allele on gene expression, which allows for identifying genes,
whose expression is affected by genetic variation, providing information on variant’s potential involvement in COVID-19 phenotype. The
output includes the levels of gene expression across all tissue types
as well as within tissues, some of which are of interest as they are
involved in lungs. eQTL-based and chromatin interaction-based mapping were used to aid the interpretation of variants identiﬁed.
2.7. Functional annotation
Functional annotation was performed with Functional Mapping
and Annotation of genetic associations (FUMA) [32] software, an
online platform for functional mapping of genetic variants from
GWAS summary statistics. Independent signiﬁcant SNPs are deﬁned
as SNPs that have a p<1x10-5 and are independent from each other
at the linkage disequilibrium threshold r2<0¢6. Therefore, independent signiﬁcant SNPs are essentially the same as SNPs that are contained after clumping GWAS tagged SNPs at the same p-value and r2.
Independent signiﬁcant SNPs are used to select candidate SNPs that
are in LD with the independent signiﬁcant SNPs. Each locus is represented by the top lead SNP that has the minimum p-value at the
locus. All SNP genomic locations are based on the NCBI37/hg19
assembly. Pairwise LD structure of SNPs was based on the 1000
Genomes Project Phase 3. Variant annotation for each locus was
made on distinct signiﬁcant SNPs and SNPs in LD with these, with a
maximum distance of 250 kb and p<0¢05, referred to as candidate
SNPs.
FUMA incorporates 18 biological data repositories and to test
whether these expressions and polygenic signal measured in each
GWAS loci clustered speciﬁc biological pathways, a gene-set analysis
was produced in Multi-marker Analysis of GenoMic Annotation
(MAGMA) [33]. MAGMA examines sets of biologically related genes
that are more strongly associated with COVID-19 hospitalizations
than other genes. This tool uses multiple linear regression models to
assess whether genes in each gene set are more strongly associated
with a polygenic trait, correcting for confounding factors such as linkage disequilibrium between variants and gene size. A gene-property
analysis was conducted using MAGMA [33] in order to indicate a the
role of particular tissue expression to gene associations, using the
GWAS summary statistics. This will evaluate whether genes with
high speciﬁcity in each cell-type are enriched for association with
COVID-19 hospitalization. With a given polygenic trait than all other
genes in this genome.

2.6. Gene annotation and expression quantitative trait loci (eQTL)
2.8. Role of the funding source
To gain insight into the potential functional roles of the signiﬁcantly associated loci, we performed enrichment to quantitative trait
analysis, cell type transcriptomics and human tissue speciﬁc expression extensively by searching publicly available data from Human

This review was commissioned as part of a project to study the
host cell receptors of coronaviruses funded by Khalifa University’s
CPRA grant (Reference number 2020-004). The funders did not have
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a role in study design, data collection, data analyses, interpretation or
writing of report.

Table 1
Demographic details of the cohort.
Non-Hospitalized
(n=164)

3. Results
3.1. Demographics of the participants
A total of 646 participants were included in this study, consisting
of non-hospitalized patients (n=164) and hospitalized patients
(n=482). Demographic data of the cohort are summarized in Table 1.
The average age was 44¢70 years (SD§15¢53), and average BMI was
28¢11 kg/m2 (SD§15¢53). Most of the participants were male (78¢6%)
of Asian (57¢0%) or Middle Eastern (36¢5%) ancestry. The distribution
of gender and ethnicity indicate a patient cohort that is representative of the many segments of the UAE population (72% male; 59%
Asian descent; 34% Middle Eastern descent)(34). The patients displayed several clinical presentations typical to COVID-19, which
mainly involved cough (65¢2%), pneumonia (52¢0%), loss of taste/
smell (47¢7%), shortness of breath (44¢1%), fatigue (41¢0%), headache
(38¢0%), body ache (35¢7%), sore throat (32¢2%), acute respiratory distress syndrome (23¢8%), chills (23¢1%), malaise (20¢6%), myalgia
(19¢6%), arthralgia (17¢8%), and nausea (13¢7%).
Consistent with previous reports, hospitalized patients tend to be
older (p<0¢001), higher BMI (p<0¢001), and with a presence of one or
more comorbidities (p<0¢001). While smoking served as a protective
factor from developing hospitalized COVID-19 symptoms (p<0¢001),
a multivariate regression analysis was performed by adjusting for
age, gender, BMI, and presence of comorbid condition, demonstrating
no association (OR: 0¢53 (95% CI: 0¢25, 1¢11); p=0¢091) between hospitalization for COVID-19 and smokers. Alcohol had no impact on disease severity (p=0¢204), even after a multivariate regression analysis
with coviariate adjustment (p=0¢837). Contrasting to previous
reports, male gender did not have a higher likelihood of developing
severe/critical disease, in comparison to female gender (p=0¢382).
Blood type was not associated with symptom severity (p=0¢136).
Among the participants that reported a comorbid condition, hospitalized COVID-19 were more likely to have a previous diagnosis of cardiac condition (p<0¢001), chronic lung disease (p<0¢001), diabetes
mellitus (p<0¢001), immunosuppressive condition (p=0¢004), neurological disorder (p=0¢020), metabolic disease (p<0¢001), and renal
disease (p=0¢018).
3.2. Identiﬁcation of susceptibility loci by genome-wide association
study
To further investigate genetic effects for the patient phenotypic
heterogeneity, we performed a genome-wide association study of
dichotomous classiﬁcation of the deﬁned “hospitalized group” that
consists of the moderate, severe, and critical ill patients (n = 482), and
the “non-hospitalized group” (n = 164) that consists of the asymptomatic and mild patients. An admixture informed principal component analysis (PCA) was plotted for the 646 participants from this
study (represented as yellow circles in the PCA plot), merged with
1092 samples from the 1000 Genomes Project v3, suggesting a multiancestry cohort with signiﬁcant population admixture and a diverse
genetic pool across various ethnic groups (Supplementary Figure 2).
To reduce technical confounders and population stratiﬁcation, the
participants were analysed separately by ethnic group depending on
the genetic threshold. GWAS analysis was carried out separately for
East Asian, South Asian, European, and American samples, followed
by a trans-ancestry meta-analysis across the four population groups.
The African ethnicity was not included in the analysis due to low
sample size (n=34). The East Asian ancestry comprised 107 participants (72 cases; 35 controls) with 7,047,811 total variants that passed
QC. The South Asian ancestry comprised 99 participants (81 cases; 18
controls) with 7,190,592 total variants that passed QC. The European
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Gender
Male
Female
Age
<15
16-30
31-45
46-60
61-75
>76
BMI
<18.50
18.51-24.50
24.51-29.99
>30.00
Self-reported ancestry
Middle East
South Asian
East Asian
African
European
Hispanic
Smoker
No
Yes
Alcohol consumer
No
Yes
Blood type
A
AB
B
O
Presence of comorbidities
No
Yes
Cardiac condition
No
Yes
Chronic lung disease
No
Yes
Diabetes mellitus
No
Yes
Immunosuppressive
condition
No
Yes
Neurological disorder
No
Yes
Metabolic disease
No
Yes
Renal disease
No
Yes

Hospitalized
(n=482)

p-value

125 (76.2%)
39 (23.8%)

383 (79.3%)
99 (20.5%)

0.382

1 (0.6%)
66 (40.2%)
79 (48.2%)
14 (8.5%)
3 (1.8%)
1 (0.6%)

7 (1.5%)
44 (9.1%)
169 (35.1%)
152 (31.5%)
91 (18.9%)
19 (3.9%)

<0.001

1 (0.9%)
44 (39.3%)
50 (44.6%)
17 (15.2%)

9 (1.9%)
95 (20.1%)
209 (44.3%)
159 (33.7%)

<0.001

35 (21.3%)
93 (56.7%)
32 (19.5%)
4 (2.4%)
0 (0.0%)
0 (0.0%)

201 (41.7%)
179 (37.1%)
64 (13.3%)
25 (5.2%)
8 (1.7%)
5 (1.0%)

92 (80.7%)
22 (19.3%)

436 (92.0%)
38 (8.0%)

<0.001

81 (91.0%)
8 (9.0%)

399 (94.5%)
23 (5.5%)

0.204

21 (22.8%)
5 (5.4%)
22 (23.0%)
44 (27.8%)

139 (32.0%)
30 (6.9%)
112 (25.7%)
154 (35.4%)

135 (84.9%)
24 (15.1%)

232 (48.9%)
242 (51.1%)

<0.001

156 (99.4%)
1 (0.6%)

267 (80.9%)
63 (19.1%)

<0.001

158 (100.0%)
0 (0.0%)

273 (91.0%)
27 (9.0%)

<0.001

150 (95.5%)
7 (4.5%)

207 (54.8%)
171 (45.2%)

<0.001

99 (99.0%)
1 (1.0%)

268 (90.2%)
29 (9.8%)

158 (100.0%)
0 (0.0%)

142 (96.6%)
5 (3.4%)

158 (100.0%)
0 (0.0%)

272 (88.0%)
37 (12.0%)

<0.001

97 (100.0%)
0 (0.0%)

204 (94.4%)
12 (5.6%)

0.018

<0.001

0.136

0.004

0.020

*p-value was measured using Pearson’s x2

ancestry comprised 302 participants (210 cases; 92 controls) with
8,615,040 total variants that passed QC. The American ancestry comprised 102 participants (90 cases; 12 controls) with 7,124,060 total
variants that passed QC. All ancestry models were adjusted for age,
gender, and population stratiﬁcation (two eigenvectors of the principal component analysis). The adjusted and unadjusted analyses of
the SNPs with a suggestive association signal (threshold
of p<5£10 5) for each of the following ancestry groups are presented
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Fig. 1. Manhattan plot of the trans-ancestry GWAS meta-analysis of 610 participants (non-hospitalized (n=157) vs. hospitalized (n=453)), highlighting eight peaks with moderate
association signal for hospitalized cases of COVID-19. The GWAS analysis results are shown on the y-axis as -log10 (p-value) and on the x-axis is the chromosomal location. The red
horizontal line illustrated the suggestive genome-wide association threshold (p<5x10-5).

in the Supplementary: East Asian population (Supplementary Figure
3, Supplementary Table 1), South Asian population (Supplementary
Figure 4, Supplementary Table 2), European population (Supplementary Figure 5, Supplementary Table 3), and American population
(Supplementary Figure 6, Supplementary Table 44). The results of the
ethnic-speciﬁc, genomic control inﬂation factor were: European
ancestry (λGC = 1.00), East Asian ancestry (λGC = 1.00), South Asian
ancestry (λGC = 1.00), and American ancestry (λGC = 1.01). A quantilequantile plot (Q-Q) plot of the meta-analyses of the four population
groups (Supplementary Figure 7) demonstrates the associations in
the tail distribution with minimal overall genomic inﬂation of the statistical results (λ GC of 0¢97 for meta-analysis).
The trans-ancestry genome-wide association meta-analysis of 610
participants (non-hospitalized (n=157) vs. hospitalized (n=453))
results identiﬁed eight loci that reached a suggestive association
threshold of p<5£10 5 (red horizontal line in Fig. 1), but no variants
surpassed a conservative Bonferroni-corrected signiﬁcance threshold
of discovery p<5£10 8. At each locus we identiﬁed the sentinel SNP
(the leading SNP with the lowest p value), with the following eight
loci that will be further elaborated in this manuscript: 2q22¢1,
2q24¢3, 5q13¢3, 11q14¢2, 13q21¢33, 13q33¢1, 14q22¢3, and 18p11¢31
(Table 2; Fig. 2 and Fig. 3). Regional association plots for the eight
newly identiﬁed loci are shown in Fig. 2. There was no evidence for
heterogeneity of effect (I2=0.00) between the ancestry groups in the
genome-wide association meta-analysis data. The complete list of
genes, their functional annotations, and all SNPs in LD associated
with hospitalized COVID-19 for the adjusted analyses are presented
in Supplementary Table 5 and Supplementary Table 6.
3.3. Gene prioritization of novel associations
3.3.1. VWA8 gene in locus 13p14¢11
Von Willebrand A Domain Containing Protein 8 (VWA8) gene
located at the 13p14¢11 locus (Fig. 2a) is localized in the mitochondria where it has a N-terminal mitochondrial targeting sequence that
allows it to export to the mitochondria organelle. It plays a role in
metabolic regulation or bioenergetic events [3]. A peak is demonstrated in this region, with the leading SNP rs10507497 (allele A; OR:
3¢12 (95% CI: 1¢98, 4¢93); p=9¢54 x10-7) marking a suggestive association signal for the development of hospitalized COVID-19 phenotypes. Even though the reported lead SNP is common in all ethnic

groups, the association signals are apparently speciﬁc to the populations of South Asian (p=6¢05 x10-3) and European ancestry (p=2¢84
x10-4). The VWA8 gene is expressed in homogenized lung tissue and
tracheal epithelium, and has previously been associated to Panlobular
emphysema, a morphologic condition associated with kyphotic chest
deformities, localized scleroses, deformities in the large bronchial airway and congenital emphysema [35,36]. The VWA8 gene leads to airway obstruction and surface tension phenomena within the lung that
progressively destroys the pulmonary contribution to homeostasis
[37]. A SNP in proxy to rs10507497 have been expressed in the Blymphocyte and lymphoblastoid (rs11842978, r2=0¢89).
3.3.2. PDE8B gene in locus 5q13¢3
Phosphodiesterase 8B (PDE8B) gene located at the 5q13¢3 locus
(Fig. 2b) catalyses the hydrolysis of the second messenger cyclic AMP
(cAMP) signalling pathway, and is involved with the thyroid function,
and is seen in the epithelium of the apical portion of the lung bronchioles, the surface of cardiomyocytes, on the surface of the epithelial-cell apical portion of the stomach and the brush border surface of
the presumptive kidney distal tubules [38]. The leading SNP of this
peak is rs7715119 (allele A; OR: 0¢34 (95% CI: 0¢22, 0¢54); p=2¢19 x106
), predominantly present in participants of European (p=1¢75 x10-5)
and American (p=4¢80 x10-2) ancestry. The expression of PDE8 in the
airway smooth muscle cells and T-lymphocytes indicate an additional
target to T-cell-mediated inﬂammation and bronchoconstriction
[39 41].
3.3.3. CTSC gene in locus 11q14¢2
Cathepsin C (CTSC) gene located at the 11q14¢2 locus (Fig. 2c) is a
lysosomal cysteine protease essential for catalytic activation of many
serine proteases. Loss-of-function mutations of CTSC result in inactivation of neutrophil serine proteases, hence leading to inﬂammatory
disease, pneumonia and viral infection [42 44]. The leading SNP of
this peak is rs72953026 (allele T; OR: 0¢35 (95% CI: 0¢23, 0¢54);
p=2¢38 x10-6), and has been associated with respiratory disorders,
cardiomyopathy, emphysema or chronic bronchitis [45]. Although
the risk allele has a consistent direction of effect and frequency across
ethnicities, an association signal was only present in the East Asian
ancestry (p=1.41 x10-2), South Asian ancestry (p=1.31 x10-2) and
European ancestry (p=7¢89 x10-4). SNPs in proxy (rs7120867,
r2=0¢87; rs72970468, r2=0¢93; rs55939583, r2=0¢93; rs11600428,

Table 2
Meta-analysed results of the susceptibility loci associated with hospitalized COVID-19 patient, stratiﬁed by ancestry (East Asian, South Asian, European and American Ancestry), associated with hospitalized COVID-19 patients. The total population included 610 participants (non-hospitalized (n=157) vs. hospitalized (n=453)). The SNPs that passed the association signal are included in this table. The p-value and corresponding odds ratio and 95% conﬁdence intervals of the minor allele
are presented.
Nearest Gene/
Cytoband

CTSC/
11q14.2
THSD7B/
2q22.1
STK39/ 2q24.3

Position
(hg19)

Allele

Trans-ancestry Meta-analysis

OR (95% CI)

P-Value

RAF

OR (95% CI)

P-Value

RAF

OR (95% CI)

P-Value

RAF

OR (95% CI)

P-Value

3.12
(1.98, 4.93)
0.34
(0.22, 0.54)
0.35
(0.23, 0.54)
0.35
(0.22, 0.54)
0.41
(0.27, 0.59)
2.10
(1.51, 2.91)
0.48
(0.34, 0.66)
0.37
(0.24, 1.22)

9.54 x10-7

0.24

0.063

0.29

0.19

0.25

0.10

0.992

0.18

1.75 x10-5

0.10

2.38 x10-6

0.21

1.31 x10-2

0.17

7.89 x10-4

0.18

-4

0.07

2.55 x10-3

0.35

-4

0.44

4.29 x10-4

0.37

-4

0.16

2.42
(0.62, 9.38)
0.21
(0.04, 0.99)
0.64
(0.21, 2.01)
0.21
(0.04, 1.03)
0.32
(0.10, 1.00)
1.86
(0.69, 4.99)
0.80
(0.32, 1.97)
0.36 (
0.09, 1.42)

0.198

0.103

3.11
(1.68, 5.74)
0.32
(0.18, 0.54)
0.36
(0.20, 0.65)
0.40
(0.23, 0.67)
0.46
(0.28, 0.76)
2.25
(1.47, 3.44)
0.46
(0.30, 0.71)
0.38
(0.22, 0.65)

2.84 x10-4

0.12

7.37
(1.77, 30.7)
1.01
(0.23, 0.43)
0.25
(0.08, 0.75)
NA

6.05 x10-3

2.19 x10-6

2.45
(0.94, 6.32)
0.34
(0.09, 1.24)
0.28
(0.10, 0.77)
0.27
(0.11, 0.69)
0.23
(0.08, 0.67)
2.02
(0.88, 4.59)
0.42
(0.19, 0.92)
0.68
(0.13, 3.46)

A

0.23

rs7715119

76675418

A

0.15

rs72953026

88169599

T

0.18

rs7605851

137706056

G

0.19

rs7595310

168810137

A

0.26

rs10140801

55730404

T

0.42

RPL6P27/ 18p11.31

rs11659676

6461230

C

0.41

G

American Ancestry

RAF

42320827

103348216

European Ancestry

P-Value

rs10507497

rs599976

South Asian Ancestry

OR (95% CI)

FBXO34/ 14q22.3

METTL21C/
13q33.1

East Asian Ancestry

RAF

0.15

-6

0.43

4.55 x10-6

0.20

3.07 x10

-6

0.38

8.88 x10-6

0.37

8.26 x10

8.95 x10

-6

0.04

1.40 x10-2

0.18

-3

0.01

7.06 x10-3

0.28

6.76 x10

0.093

0.38

2.99 x10-2

0.42

0.643

0.22

0.45
(0.17, 1.22)
1.81
(0.76, 4.32)
0.41
(0.16, 0.99)
0.27
(0.09, 0.75)

0.21
0.116

0.24

0.179

0.43

4.80 x10-2

0.43

1.22 x10

-2

0.16

CI: Conﬁdence Interval; NA: Not Applicable; RAF: Rare Allele Frequency; SNP: Single Nucleotide Polymorphism; OR: Odds Ratio.
Nearest gene indicates gene either harbouring the variant or nearest to it.
East Asian Ancestry: 107 participants (72 cases; 35 controls); 7047811 total variants that passed QC.
South Asian Ancestry: 99 participants (81 cases; 18 controls); 7190592 total variants that passed QC.
European Ancestry: 302 participants (210 cases; 92 controls); 8615040 total variants that passed QC.
American Ancestry: 102 participants (90 cases; 12 controls); 7124060 total variants that passed QC.
Trans-ancestry GWAS Meta-Analysis (ﬁxed effect): 610 participants (453 cases; 157 controls); 7750527 total variants that passed QC; heterogeneity (I2) in the reported SNPs was 0.00.
Additive effect of variant was applied for all models corrected for population stratiﬁcation with adjustment to 2 principal components, age, and gender, and p-value was measured using Pearson’s x2.
Monomorphic or minor allele frequency (<0.01) for the South Asian population in 1000 Genomes South Asian populations; http://useast.ensembl.org/index.html.

6.42 x10

1.78 x10

5.33 x10

4.80 x10-2
0.453
0.054
0.051
0.22
0.63
0.145
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VWA8/
13q14.11
PDE8B/ 5q13.3

Lead SNP
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Fig. 2. Regional plots for association of genotyped and imputed SNPs in the trans-ancestry GWAS meta-analysis in association to hospitalized COVID-19. SNPs are plotted according
to their chromosomal position (NCBI Build 37) with -log10 p-values on the y-axis, and the relative location of the annotated genes and the direction of transcription are shown in
the lower portion of the Fig. The most strongly associated SNP is shown as a small purple circle. Linkage disequilibrium (LD; R2 values) between the lead SNP and the other SNPs is
indicated using red colours. The colour scheme indicated the LD displayed as r2 values between all SNPs and the top-ranked SNP in each plot. Top-ranked SNPs are shown as purple
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Fig. 3. Functional annotation and eQTL expression in the Lung tissue obtained from Human Protein Atlas database: (a) immunologic signature of the proportion of overlapping
genes (FBXO34, STK39, PDE8B); b) heatmap of GTEx v8 30 general tissue types and the average expression per label (log2 transformed); c) VWA8 gene in locus 13p14¢11, (d) PDE8B
gene in locus 5q13¢3, (e) CTSC gene in locus 11q14¢2, (f) STK39 gene in locus 2q24¢3; (g) FBXO34 gene in locus 14q22¢3.

diamonds in the top of each chromosomal locus: (a) 13q14¢11, (b) 5q13¢3, (c)11q14¢2, (d) 2q22¢1, (e) 2q24¢3, (f) 14q22¢3, (g) 18p11¢31, and (h) 13q33¢1. The blue lines represent the
estimated recombination rates. Plots are generated using LDlink.
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r2=1¢00; rs72953026, , r2=1¢00) to the lead SNP has been associated to
lung ﬁbroblasts and B-lymphocyte.
3.3.4. THSD7B gene in locus 2q22¢1
Thrombospondin Type-1 Domain-Containing 7 (THSD7B) gene at
the 2q22¢1 locus (Fig. 2d) is a membrane-associated N-glycoprotein
that mediates endothelial cell migration, cytoskeletal organization,
and tube formation. This gene has been identiﬁed in GWAS in association with tumour progression such as pancreatic cancer [46], melanoma [47], and non-small lung cancer [1]. The leading SNP of this
peak is rs7605851 (allele G; OR: 0¢35 (95% CI: 0¢22, 0¢54); p=3¢07
x10-6). The THSD7B receptor is a target in the diagnosis and treatment
of idiopathic membranous nephropathy(2). Translating this knowledge into the patho-mechanistic understanding of COVID-19 severity
could be in association to immune-complex formation and subsequent molecular injury signalling. When assessing the association of
this SNP between ancestry groups, this SNP was found to be monomorphic in the South Asian ancestry. While the magnitude and direction of odds ratio was consistent between the other ethnic groups,
the association signals are apparently speciﬁc to the populations of
East Asian (p=6¢76 x10-3) and European ancestry (p=6¢42 x10-4).
3.3.5. STK39 gene in locus 2q24¢3
Serine/Threonine Kinase 39 (STK39) at the 2q24¢3 locus (Fig. 2e)
encodes a serine/threonine kinase that is thought to function in the
cellular stress response pathway and acts as MAPK kinase and
involved in stress response via activating p38 MAPK. The leading SNP
of this peak is rs7595310 (allele A; OR: 0¢41 (95% CI: 0¢27, 0¢59);
p=4¢55 x10-6), predominantly present in the East Asian (p=7¢06 x103
) and European ancestry (p=2¢55 x10-3). This gene has been strongly
associated with cancer-related process and pathway, speciﬁcally
non-small cell type lung cancer [48]. In addition, SNPs in linkage disequilibrium to the lead SNP in gene STK39 has been associated to
hypertension, mainly due to the involvement of STK39 in sodium
reabsorption and salt homeostasis [48 53].
3.3.6. FBXO34 gene in locus 14q22¢3
The F-Box Protein 34 (FBXO34) gene in locus 14q22.3
(Fig. 2f) regulate proteins involved in differentiation and cell cycle
progression including the Wnt signalling pathway [54]. Previous
GWAS have identiﬁed the association of FBXO34 gene to blood
protein levels in cardiovascular risk, as well as leucocyte, reticulocyte and platelet count [55 58]. The leading SNP of this peak is
rs10140801 (allele T; OR: 2.10 (95% CI: 1.51, 2.91); p=8.26 x10-6).
While the magnitude and direction of odds ratio was consistent
between the other ethnic groups, the association signals are
apparently speciﬁc to the population of European ancestry
(p=1.78 x10-4). SNPs in proxy (rs11547116, r2=0.95; rs943590,
r2=0.96; rs7146752, r2=0.97; rs13379169, r2=0.96; rs72715769,
r2=0.91; rs58260073, r2=0.90; rs10140869, r2=0.89; rs11625423,
r2=0.86) to the lead SNP has been associated to lung ﬁbroblasts
and B-lymphocyte expression.
3.3.7. RPL6P27 gene in locus 18p11¢31
Ribosomal Protein L6 Pseudogene 27 (RPL6P27) is in an intergenic
region in locus 18p11¢31 (Fig. 2g), and have been associated to ventricular arrhythmias, and circulating cytokine and growth levels. The
leading SNP of this peak is rs11659676 (allele C; OR: 0¢48 (95% CI:
0¢34, 0¢66); p=8¢88 x10-6), with a similar magnitude and direction of
odds ratio present across the East Asian (p=2¢99 x10-2), South Asian
(p=4¢80 x10-2) and European ancestry (p=4¢29 x10-4). The lead SNP
has been expressed in lung ﬁbroblast cells, T cells and B cells, which
may lead to inﬂammation, alleviate tissue damage, mediate the cytokine storm and lead to a higher severity of symptoms associated to
COVID-19.

3.3.8. METTL21C gene in locus 13q33¢1
Methyltransferase 21C, AARS1 Lysine (METTL21C) in locus
13q33¢1 (Fig. 2h) is a suggestive pleiotropic gene for bone and muscle, and the METTL21 family of proteins methylates chaperons that
are involved in the aetiology of myopathy and regulation of the NFkB signalling pathway, which is critical for bone and muscle homeostasis [59]. While the METTL21C gene may not have a direct effect on
COVID-19 symptom severity, its association to the NF-kB signalling
pathway may play a role in the expression of diverse cellular processes, including proliferation, survival, and immunity. In addition,
the NF-kB family may also play a role in the production of inﬂammatory cytokines, enhancement of airway epithelium, increased airway
neutrophilic and lymphocytic inﬂammation and goblet cell hyperplasia [60,61]. The leading SNP of this peak is rs599976 (allele G; OR:
0¢37 (95% CI: 0¢24, 1¢22); p=8¢95 x10-6), with a predominant signiﬁcant association signal in the South Asian (p=1¢22 x10-2) and European ancestry (p=5¢33 x10-4).
3.4. eQTL and functional annotation in the lung domain
A MAGMA-gene property analysis was conducted to investigate
the association of the gene-property analysis with a full distribution
of SNP p-values to differentially expressed genes (Supplementary
Table 7). This demonstrated that a total of 56 genes are involved in Bcell receptor signalling, angiogenesis, and lymphomagenesis, leading
to the association to COVID-19 hospitalization (p=2¢87x10-5). These
genes play a key role in modifying the response of cells of lymphoid
origin (such as B, T and NK cells) to self and tumour antigens, leading
to B cell chronic lymphocytic leukaemia, as well as to viral infections
like COVID-19 [62,63]. Given the potential importance of immunopathological complications in severe COVID-19 disease, regulation of
these genes are critical to B cell receptor signalling, the chemokine
signalling pathway, and decreases the inﬂuence of activated CD4+ T
cells to inﬁltrate and damage lung organs in the future [64]. This
plays a signiﬁcant role in the immune response, inﬂammation and
cytokine storm through gene expression that leads to critical cases of
COVID-19 infection.
After identifying the GWAS variants that have demonstrated a
suggestive genetic association, SNP and gene enrichment analysis
was conducted on cell types, speciﬁcally related to enrichment in
gene expression across lung tissue. Multiple comprehensive eQTL
mapping resources for proﬁling traits based on gene expression was
conducted, including GTEx v7, Human Protein Atlas, and MAGMA
analysis in FUMA. A signiﬁcant (p=9¢66x10-6) overlap of the following
immunologic gene sets (FBXO34, STK39, PDE8B) was present, demonstrating an association to COVID-19 hospitalization (Fig. 3a). Speciﬁcally, the immunologic gene set is involved in the expression of IFNalpha and CD8 T-cells, and their response to antigen and costimulatory signals all play a signiﬁcant role in the cytokine storm of the progression of symptoms associated to COVID-19. The identiﬁed COVID19 gene associations were also enriched in the lung tissue, demonstrating an important role in lung function and pulmonary immune
response (Fig. 3b). To investigate the overlap of individual gene
expression to transcriptomics data integrated with lung expression
and the immune system, a heatmap demonstrates that the following
ﬁve genes were highly conserved across tissues and donors located
in the lung (Fig. 2c-g): VWA8, PDE8B, CTSC, STK39, and FBXO34,
respectively. Expression of these genes are associated to alveolar cells
type 1 and 2, ciliated cells, club cells, B-cells, dendritic cells, granulocytes, macrophages, monocytes, NK-cells, T-cells, intestinal endocrine
cells, ﬁbroblasts, smooth muscle cells, and endothelial cells.
4. Discussion
We have discovered eight genes with a suggestive association to
hospitalized cases of COVID-19 by studying the genome, functional
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annotation, eQTL enrichment analysis and clinical outcome of 646
patients in multiple designated hospitals and quarantine camps in
the UAE. We evaluated the association of genetic variants with
COVID-19 severity using GWAS to improve the understanding of
potentially causal molecular targets for SARS-CoV-2. We designed
our current approach of trans-ancestry meta-analysis to uncover
genetic variants shared across ancestry groups. Although the discovery of the eight loci were largely driven by effects in the European
ancestry populations, the magnitude and direction of allelic effect
were similar in multiple ancestral populations, demonstrating the
chances of those variants modulating the risk of infection and severe
COVID-19 symptoms in different populations.
When investigating non-genetic effects, hospitalized patients for
COVID-19 tend to be older (p<0¢001), higher BMI (p<0¢001), and
with a presence of one or more comorbidities (p<0¢001), similar to
published literature [9,10,14,65 67]. Mortality is predominantly
driven by these subgroups of patients with comorbid conditions,
which includes cardiac conditions, chronic lung disease, diabetes
mellitus, immunosuppressive condition, neurological disorder, metabolic disease, and renal disease. Contrasting to previous reports, male
gender did not have a higher likelihood of developing severe/critical
disease, in comparison to female gender (p=0¢382). After multivariate
regression analysis, smoking (p=0¢091) and alcohol (p=0¢837) had no
impact on COVID-19 disease severity.
Eight genes demonstrated a strong association signal: VWA8 gene
in locus 13p14¢11 (SNP rs10507497; p=9¢54 x10-7), PDE8B gene in
locus 5q13¢3 (SNP rs7715119; p=2¢19 x10-6), CTSC gene in locus
11q14¢2 (rs72953026; p=2¢38 x10-6), THSD7B gene in locus 2q22¢1
(rs7605851; p=3¢07x10-6), STK39 gene in locus 2q24¢3 (rs7595310;
p=4¢55 x10-6), FBXO34 gene in locus 14q22¢3 (rs10140801; p=8¢26
x10-6), RPL6P27 gene in locus 18p11¢31 (rs11659676; p=8¢88 x10-6),
and METTL21C gene in locus 13q33¢1 (rs599976; p=8¢95 x10-6). The
genes are expressed in the lung, associated to tumour progression,
emphysema, airway obstruction, and surface tension within the lung,
as well as an association to T-cell-mediated inﬂammation and the
production of inﬂammatory cytokines(1 3). The signals observed of
these genes are associated with respiratory failure that requires invasive mechanical ventilation.
Functional annotation can help prioritise the associations of the
genes of interest. When investigating the association of the GWAS
summary statistics to the MAGMA-gene property analysis, a total of
56 genes are involved in B-cell receptor signalling, angiogenesis, and
lymphomagenesis, leading to the association of COVID-19 hospitalization (p=2¢87x10-5). These genes play a key role in modifying the
response of cells of lymphoid origin (such as B, T and NK cells) to self
and tumour antigens, leading to B cell chronic lymphocytic leukaemia, as well as to viral infections like COVID-19 [62,63]. Given the
potential importance of immunopathological complications in severe
COVID-19 disease, regulation of these genes are critical to B cell
receptor signalling, the chemokine signalling pathway, and decreases
the inﬂuence of activated CD4+ T cells to inﬁltrate and damage lung
organs in the future [64]. This plays a signiﬁcant role in the immune
response, inﬂammation and cytokine storm through gene expression
that leads to critical cases of COVID-19 infection. Consistent with the
large degree of pleiotropy between disorders, cell-type enrichment
analysis demonstrated that there was an enrichment for lung tissue
expression and donors, speciﬁcally with genes VWA8, PDE8B, CTSC,
STK39, and FBXO34.
There are several potential limitations in our study. There are
methodological drawbacks with the small sample size and study
design, as the power analysis indicated that sample size is barely sufﬁcient to identify genome-wide signiﬁcant variants. However,
because of the urgency of completing and reporting the ﬁndings of
this study, we have published the ﬁndings, as opposed to waiting to
meet sample size requirement. It should be noted that given the
small sample size, this study is a purely descriptive, hypothesis-
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generating phase of research that is required to be replicated in larger
studies of Middle Eastern and South Asian ancestry. Therefore, a
multi-ethnic cohort with a larger sample size would be more suited
to investigate these genetic associations that have been identiﬁed in
this manuscript. There is a clear predominance of males (78.6%) of
Asian ancestry (57.0%) in this cohort, a limitation that the results are
skewed for a speciﬁc demographic group. However, the demographic
factors in this cohort is fairly distributed and representative of the
UAE population, where 72% of the population are male of Asian
descent (59%) [34]. While most of the population was of self-reported
Middle Eastern and South Asian descent, the population composition
is a mixed genetic pool, as demonstrated by the PCA plot (Supplementary Fig. 2). However, to reduce technical confounders and population stratiﬁcation, the participants were analysed separately by
ethnic group depending on the genetic threshold. GWAS analysis
was carried out separately for East Asian, South Asian, European, and
American samples, followed by a trans-ancestry meta-analysis across
the four population groups that demonstrates the associations in the
tail distribution with minimal overall genomic inﬂation of the statistical results (λ GC of 0¢97 for meta- analysis). To improve statistical
power for genomic discovery, covariates, such as age, gender, and
population stratiﬁcation, are included to account for stratiﬁcation
and avoid confounding effects from demographic factors. Due to the
inclusion of multiple data collection sites from across the country, it
is possible that the included cases, although all were hospitalized
COVID-19 patients, are not entirely homogeneous. It is possible that
the criteria for hospitalization of COVID-19 patients are different
across the collection sites, thus measurement errors may exist in this
study. Given that most of the participants were recruited from the
hospital, we had limited number of participants who had asymptomatic or mild symptoms as they were more likely to quarantine at
home. This may raise the concern that the pathological differences
between the cases and the controls may be relatively subtle. The
strength of this study was limiting misclassiﬁcation and ascertainment biases in the control group by only selecting COVID positive
patients with asymptomatic or mild symptoms, whereas other GWAS
studies have utilized population controls. The use of population
controls might mean that the SNPs identiﬁed are associated with
susceptibility of COVID-19, as opposed to the association with
severe COVID-19, a limitation that has been identiﬁed by other
authors using population controls. The use of Euro-centric GWAS
arrays limits the possibility of including targeted SNPs in the
genome. To limit this error, imputation of genotypes for genetic
variants that are untyped in the arrays increases the information
provided by each microarray by accurately evaluating the evidence for association at genetic markers that are not directly genotyped [68].
We have discovered eight highly plausible genetic association
with hospitalized cases in COVID-19. Our ﬁndings implicate that the
different lung response to the virus determined by host genetic diversity may be an important factor in determining the severity of COVID19. Further functional studies are warranted to establish the roles of
these eight loci in the pathogenesis of COVID-19. Some of these associations may lead to therapeutic approaches due to the expression in
the lungs. Improving fundamental knowledge and underlying biological pathway of COVID-19 heterogenous phenotypes is critical to mitigating this disease. Performing GWAS studies across different racial
and ethnic populations to identify genes and haplotypes associated
with differential factors of infection and clinical outcome, as well as
vaccine responses, is crucial. Allelic effect size differences could
reﬂect interaction of the causal variant with environmental risk factors that differ in exposure between ethnicities. Further studies must
be conducted on a large-scale multi-ethnic cohort to expand and substantiate our current knowledge, as well as facilitate the development of population speciﬁc therapeutics to mitigate this worldwide
challenge.
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